-
A Clinical Study of MK-2214 in People With Early Alzheimer's Disease (MK-2214-004)
NCT07033494 ·
Phase: Phase 2 ·
Ages: 50 Years to 85 Years ·
Sex: All (male and female)
· Pennsylvania: Plymouth Meeting
-
A Clinical Trial of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease
NCT07170150 ·
Phase: Phase 3 ·
Ages: 50 Years to 90 Years ·
Sex: All (male and female)
· Pennsylvania: Plymouth Meeting
-
A Clinical Trial to Learn About the Effects of VHB937 in People With Early Alzheimer's Disease
NCT07094516 ·
Phase: Phase 2 ·
Ages: 50 Years to 85 Years ·
Sex: All (male and female)
· Pennsylvania: Willow Grove
-
A Study of Donanemab (LY3002813) in Participants With Early Cognitive Decline (TRAILBLAZER-ALZ 7)
NCT07589595 ·
Phase: Phase 2 ·
Ages: 55 Years to 85 Years ·
Sex: All (male and female)
· Pennsylvania: Philadelphia
-
A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation
NCT05552157 ·
Phase: Phase 2, Phase 3 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Pennsylvania: Pittsburgh
-
A Study of a Potential Disease Modifying Treatment in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation
NCT06647498 ·
Phase: Phase 2, Phase 3 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Pennsylvania: Pittsburgh
-
A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-1)
NCT05511363 ·
Phase: Phase 3 ·
Ages: 55 Years to 90 Years ·
Sex: All (male and female)
· Pennsylvania: Allentown
-
A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-2)
NCT06126224 ·
Phase: Phase 3 ·
Ages: 55 Years to 90 Years ·
Sex: All (male and female)
· Pennsylvania: Malvern
-
A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease
NCT06976216 ·
Phase: Phase 3 ·
Ages: 60 Years to 85 Years ·
Sex: All (male and female)
· Pennsylvania: Abington
-
A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease (MINDSET 2)
NCT06976203 ·
Phase: Phase 3 ·
Ages: 60 Years to 85 Years ·
Sex: All (male and female)
· Pennsylvania: Plymouth Meeting
-
ACP-204 in Adults With Alzheimer's Disease Psychosis
NCT06159673 ·
Phase: Phase 2, Phase 3 ·
Ages: 55 Years to 95 Years ·
Sex: All (male and female)
· Pennsylvania: Abington
-
Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant
NCT06563895 ·
Phase: Phase 3 ·
Ages: 18 Years to 75 Years ·
Sex: All (male and female)
· Pennsylvania: Philadelphia, Pittsburgh
-
Biofluid Research on Age-Related or Inherited Neurodegeneration
NCT07798700 ·
Phase: Not specified ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Pennsylvania: Philadelphia
-
Characterizing Cognitive Decline in Late Life Depression: The ADNI Depression Project
NCT02434393 ·
Phase: Not specified ·
Ages: 65 Years and older ·
Sex: All (male and female)
· Pennsylvania: Pittsburgh
-
Development of a Database to Investigate Digital and Blood-Based Biomarkers and Their Relationship to Tau and Amyloid PET Imaging in Older Participants Who Are Cognitively Normal (CN), Have Mild Cognitive Impairment (MCI), or Have Mild-to-Moderate AD Dementia
NCT06584357 ·
Phase: Not specified ·
Ages: 60 Years to 90 Years ·
Sex: All (male and female)
· Pennsylvania: Philadelphia
-
Dominantly Inherited Alzheimer Network (DIAN)
NCT00869817 ·
Phase: Not specified ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Pennsylvania: Pittsburgh
-
Evaluating Novel Healthcare Approaches to Nurturing and Caring for Hospitalized Elders
NCT05929703 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: 70 Years and older ·
Sex: All (male and female)
· Pennsylvania: Philadelphia, Pittsburgh
-
Evaluating the Effectiveness of the Health App Recommendation Tool
NCT07216716 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: 18 Years to 65 Years ·
Sex: All (male and female)
· Pennsylvania: Pittsburgh
-
Impact of a Biophoton Therapy on Patients With Brain Disorders
NCT06147999 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Pennsylvania: Butler
-
Improving Access to Care for Veterans With Memory Loss
NCT07117162 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Pennsylvania: Pittsburgh
-
Late Onset Alzheimer's Disease
NCT05010603 ·
Phase: Not specified ·
Ages: 55 Years and older ·
Sex: All (male and female)
· Pennsylvania: Pittsburgh
-
PET Imaging Tau Accumulation in FTLD and Atypical Alzheimer's Using [18F]-PI-2620
NCT05456503 ·
Phase: Phase 3 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Pennsylvania: Philadelphia
-
Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies
NCT07177352 ·
Phase: Phase 3 ·
Ages: 50 Years to 90 Years ·
Sex: All (male and female)
· Pennsylvania: Plymouth Meeting
-
Study of Biodistribution, Metabolism, Excretion and Brain Uptake 18F-JSS20-183A
NCT06932809 ·
Phase: Early Phase 1 ·
Ages: 40 Years to 85 Years ·
Sex: All (male and female)
· Pennsylvania: Philadelphia
-
Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986368, for the Treatment of Agitation in Participants With Alzheimer's Disease
NCT06808984 ·
Phase: Phase 2 ·
Ages: 55 Years to 90 Years ·
Sex: All (male and female)
· Pennsylvania: Philadelphia
-
Tau PET/CT Imaging in the Mismatch Prospective Cohort Study (MPC-TAU)
NCT05658913 ·
Phase: Not specified ·
Ages: 18 Years to 120 Years ·
Sex: All (male and female)
· Pennsylvania: Philadelphia
-
The Effects of Successful OSA Treatment on Memory and AD Biomarkers in Older Adults Study
NCT05988385 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: 55 Years to 85 Years ·
Sex: All (male and female)
· Pennsylvania: Pittsburgh
-
Trial-Ready Cohort-Down Syndrome (TRC-DS)
NCT04165109 ·
Phase: Not specified ·
Ages: 25 Years to 55 Years ·
Sex: All (male and female)
· Pennsylvania: Pittsburgh
-
UPenn Observational Research Repository on Neurodegenerative Disease
NCT04715399 ·
Phase: Not specified ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Pennsylvania: Philadelphia
-
Using the EHR to Advance Genomic Medicine Across a Diverse Health System
NCT06377033 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Pennsylvania: Philadelphia